BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 21476870)

  • 1. In vitro conversion and seeded fibrillization of posttranslationally modified prion protein.
    Stöhr J; Elfrink K; Weinmann N; Wille H; Willbold D; Birkmann E; Riesner D
    Biol Chem; 2011 May; 392(5):415-21. PubMed ID: 21476870
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assembly of natural and recombinant prion protein into fibrils.
    Leffers KW; Wille H; Stöhr J; Junger E; Prusiner SB; Riesner D
    Biol Chem; 2005 Jun; 386(6):569-80. PubMed ID: 16006244
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The structural transition of the prion protein into its pathogenic conformation is induced by unmasking hydrophobic sites.
    Leffers KW; Schell J; Jansen K; Lucassen R; Kaimann T; Nagel-Steger L; Tatzelt J; Riesner D
    J Mol Biol; 2004 Nov; 344(3):839-53. PubMed ID: 15533449
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preventing misfolding of the prion protein by trimethylamine N-oxide.
    Bennion BJ; DeMarco ML; Daggett V
    Biochemistry; 2004 Oct; 43(41):12955-63. PubMed ID: 15476389
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Truncated PrP(c) in mammalian brain: interspecies variation and location in membrane rafts.
    Laffont-Proust I; Hässig R; Haïk S; Simon S; Grassi J; Fonta C; Faucheux BA; Moya KL
    Biol Chem; 2006 Mar; 387(3):297-300. PubMed ID: 16542151
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Spontaneous and BSE-prion-seeded amyloid formation of full length recombinant bovine prion protein.
    Panza G; Stöhr J; Dumpitak C; Papathanassiou D; Weiss J; Riesner D; Willbold D; Birkmann E
    Biochem Biophys Res Commun; 2008 Sep; 373(4):493-7. PubMed ID: 18585368
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interaction of the cellular prion protein with raft-like lipid membranes.
    Elfrink K; Nagel-Steger L; Riesner D
    Biol Chem; 2007 Jan; 388(1):79-89. PubMed ID: 17214553
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential solubility of prions is associated in manifold phenotypes.
    Kuczius T; Karch H; Groschup MH
    Mol Cell Neurosci; 2009 Nov; 42(3):226-33. PubMed ID: 19607920
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of oligomeric prion-protein aggregates in a mouse model of prion disease.
    Sasaki K; Minaki H; Iwaki T
    J Pathol; 2009 Sep; 219(1):123-30. PubMed ID: 19479969
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro conversion of full-length mammalian prion protein produces amyloid form with physical properties of PrP(Sc).
    Bocharova OV; Breydo L; Parfenov AS; Salnikov VV; Baskakov IV
    J Mol Biol; 2005 Feb; 346(2):645-59. PubMed ID: 15670611
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural changes of the prion protein in lipid membranes leading to aggregation and fibrillization.
    Kazlauskaite J; Sanghera N; Sylvester I; Vénien-Bryan C; Pinheiro TJ
    Biochemistry; 2003 Mar; 42(11):3295-304. PubMed ID: 12641461
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prion-protein-specific aptamer reduces PrPSc formation.
    Proske D; Gilch S; Wopfner F; Schätzl HM; Winnacker EL; Famulok M
    Chembiochem; 2002 Aug; 3(8):717-25. PubMed ID: 12203970
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sulfated glycans and elevated temperature stimulate PrP(Sc)-dependent cell-free formation of protease-resistant prion protein.
    Wong C; Xiong LW; Horiuchi M; Raymond L; Wehrly K; Chesebro B; Caughey B
    EMBO J; 2001 Feb; 20(3):377-86. PubMed ID: 11157745
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of rafts in the fibrillization and aggregation of prions.
    Pinheiro TJ
    Chem Phys Lipids; 2006 Jun; 141(1-2):66-71. PubMed ID: 16647049
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural intermediates in the putative pathway from the cellular prion protein to the pathogenic form.
    Jansen K; Schäfer O; Birkmann E; Post K; Serban H; Prusiner SB; Riesner D
    Biol Chem; 2001 Apr; 382(4):683-91. PubMed ID: 11405232
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Methionine sulfoxides on PrPSc: a prion-specific covalent signature.
    Canello T; Engelstein R; Moshel O; Xanthopoulos K; Juanes ME; Langeveld J; Sklaviadis T; Gasset M; Gabizon R
    Biochemistry; 2008 Aug; 47(34):8866-73. PubMed ID: 18680312
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Scrapie prion protein structural constraints obtained by limited proteolysis and mass spectrometry.
    Sajnani G; Pastrana MA; Dynin I; Onisko B; Requena JR
    J Mol Biol; 2008 Sep; 382(1):88-98. PubMed ID: 18621059
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Mechanisms of prion transmission].
    Sakaguchi S
    Nihon Rinsho; 2007 Aug; 65(8):1391-5. PubMed ID: 17695274
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Self-assembly of recombinant prion protein of 106 residues.
    Baskakov IV; Aagaard C; Mehlhorn I; Wille H; Groth D; Baldwin MA; Prusiner SB; Cohen FE
    Biochemistry; 2000 Mar; 39(10):2792-804. PubMed ID: 10704232
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Post-translational hydroxylation at the N-terminus of the prion protein reveals presence of PPII structure in vivo.
    Gill AC; Ritchie MA; Hunt LG; Steane SE; Davies KG; Bocking SP; Rhie AG; Bennett AD; Hope J
    EMBO J; 2000 Oct; 19(20):5324-31. PubMed ID: 11032800
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.